Form PRE 14A - Other preliminary proxy statements:
SEC Accession No. 0000950170-25-053024
Filing Date
2025-04-11
Accepted
2025-04-11 07:11:48
Documents
20
Period of Report
2025-04-11

Document Format Files

Seq Description Document Type Size
1 PRE 14A tngx-20250411.htm   iXBRL PRE 14A 1695207
2 GRAPHIC img161881671_0.jpg GRAPHIC 18128
3 GRAPHIC img161881671_1.jpg GRAPHIC 18128
4 GRAPHIC img161881671_2.jpg GRAPHIC 18128
5 GRAPHIC img161881671_3.jpg GRAPHIC 69377
6 GRAPHIC img161881671_4.jpg GRAPHIC 48235
7 GRAPHIC img161881671_5.jpg GRAPHIC 469376
8 GRAPHIC img161881671_6.jpg GRAPHIC 182495
  Complete submission text file 0000950170-25-053024.txt   4260777

Data Files

Seq Description Document Type Size
9 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT tngx-20250411.xsd EX-101.SCH 8827
22 EXTRACTED XBRL INSTANCE DOCUMENT tngx-20250411_htm.xml XML 193539
Mailing Address 201 BROOKLINE AVENUE SUITE 901 BOSTON MA 02215
Business Address 201 BROOKLINE AVENUE SUITE 901 BOSTON MA 02215 (857) 320-4900
Tango Therapeutics, Inc. (Filer) CIK: 0001819133 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: PRE 14A | Act: 34 | File No.: 001-39485 | Film No.: 25829848
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)